ALS

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NYCB, Amylyx, Xponential, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 30, 2024
SSS, Signature, Vii, Apoptosis, ALS, Patient, AUV, Bloomberg Businessweek, ACL, Food and Drug Administration, Defendant, AMX0035, Amyotrophy, Sale, News, Dermatology, Prescription, New York Community Bank, NYCB, IBD, Complaint, P.C, Geisler, Investor's Business Daily, Assumption, Confidentiality, Amylyx Pharmaceuticals, Injury, Category, Dentist, FDA, BBC World Service, Evercore, Food, Pharmaceutical industry

NYCB is a large commercial-real estate lender in the New York City market area, where it specializes in rent-regulated, non-luxury apartment buildings.

Key Points: 
  • NYCB is a large commercial-real estate lender in the New York City market area, where it specializes in rent-regulated, non-luxury apartment buildings.
  • NYCB is engaged in several national businesses, including multi-family lending, mortgage originations and servicing, and warehouse lending.
  • On January 31, 2024, before the market opened, NYCB announced its fiscal fourth quarter 2023 financial results.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

Amylyx Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 9, 2024 deadline.

Retrieved on: 
Thursday, March 28, 2024
Patient, Defendant, Apoptosis, ALS, Pharmaceutical industry

LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).

Key Points: 
  • LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 310-692-8883 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)

Retrieved on: 
Thursday, March 28, 2024
ALS, Patient, GPM, Defendant, News, Suite, Investment, GAAP, Court, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On November 9, 2023, Amylyx released its third quarter 2023 financial results, missing GAAP earnings per share consensus estimates by approximately 29%.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Amylyx Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 – AMLX

Retrieved on: 
Thursday, March 28, 2024
Apoptosis, ALS, Telephone, Patient, LLP, CLASS, NEXT, COST, Court, Cryptocurrency

NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amylyx investors who were adversely affected by alleged securities fraud between November 11, 2022 and November 8, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    AMLX investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Amylyx Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 – AMLX

Retrieved on: 
Thursday, March 28, 2024
Apoptosis, ALS, Telephone, Patient, LLP, CLASS, NEXT, COST, Court, Cryptocurrency

NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amylyx investors who were adversely affected by alleged securities fraud between November 11, 2022 and November 8, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    AMLX investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders

Retrieved on: 
Wednesday, March 27, 2024
NEXT, Amylyx Pharmaceuticals, Patient, Apoptosis, Fraud, ALS, Security (finance)

NEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX).

Key Points: 
  • NEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX).
  • Shareholders who purchased shares of AMLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 26, 2024
Apoptosis, Patient, AMX0035, Science, New York Community Bank, NYCB, P.C, Initiative, ACL, Scientific misconduct, IBD, Confidentiality, Safety, Injury, Data management, Food, Signature, Cassava Sciences, ALS, Alzheimer's disease, Defendant, Food and Drug Administration, Journal, Amyotrophy, News, Prescription, Amylyx Pharmaceuticals, Dentist, FDA, City University, Biomarker, Dermatology, Complaint, Investor's Business Daily, Neurobiology of Aging, Cognition, Assumption, Category, BBC World Service, Evercore, Cassava, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)

Retrieved on: 
Monday, April 8, 2024
Class Action Lawsuit, Professional Services, Legal, Law, ALS, Patient, Defendant, News, Suite, GAAP, Court, Pharmaceutical industry

On November 9, 2023, Amylyx released its third quarter 2023 financial results, missing GAAP earnings per share consensus estimates by approximately 29%.

Key Points: 
  • On November 9, 2023, Amylyx released its third quarter 2023 financial results, missing GAAP earnings per share consensus estimates by approximately 29%.
  • On this news, Amylyx’s stock price fell $5.74, or 31.9%, to close at $12.26 per share on November 9, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, ALS, Biomarker, Research, Acquisition, Patient, Investment

This agreement provides NeuroSense with access to Lonza's unparalleled, state-of-the-art extracellular vesicles expertise and capabilities quickly and on an 'on-demand' basis, without further commitments.

Key Points: 
  • This agreement provides NeuroSense with access to Lonza's unparalleled, state-of-the-art extracellular vesicles expertise and capabilities quickly and on an 'on-demand' basis, without further commitments.
  • NeuroSense will leverage its extensive experience in biomarker utilization in neurodegenerative diseases.
  • Our 'Dev-on-Demand' solution provides NeuroSense with access to expert scientists working in state-of-the-art laboratories for their development activities.
  • The team and platform make Lonza the partner of choice for NeuroSense to identify exosomes-based biomarkers."

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

Retrieved on: 
Tuesday, April 9, 2024
Neurology, Neuroprotection, Element, Conference call, Institutional review board, Cerebrospinal fluid, Survival, Disease, ALS, SPA, Bone marrow, CSF, Data monitoring committee, Webcast, Patient, Protocol, Biomarker, Mortality, Microsoft Exchange Server, Stem cell, DMC, Screening, Agency, Safety, CAFS, Brainstorm, Therapy, Marketing, FDA, BLA, Neuroinflammation, Food, Pharmaceutical industry

NEW YORK, April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS). 

Key Points: 
  • (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS).
  • The SPA agreement with the FDA validates the clinical trial protocol and statistical analysis of the planned Phase 3b trial of NurOwn, demonstrating their adequacy for addressing objectives that support a future BLA (Biologics License Application) in ALS.
  • We appreciate the Agency's engagement and guidance during the SPA process and look forward to moving forward with the study."
  • The Phase 3b trial (Study BCT-006-US) will be a two-part, multicenter, study designed to assess the efficacy and safety of NurOwn in patients with ALS.